Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brickell Biotech, Inc.

https://brickellbio.com/

Latest From Brickell Biotech, Inc.

China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer

CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.

China Vaccines

Sobi Maintains Grip On RSV Market – For Now

Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.

Respiratory Rare Diseases

Next Potential Big ADC Player? Korean Firms Take It Up A Notch

Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.

South Korea Research & Development

Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist

Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Vical, Inc.
    • Vical Incorporated (VICL)
UsernamePublicRestriction

Register